Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

被引:55
作者
Agha, Mounzer E. [1 ]
Blake, Maggie [1 ]
Chilleo, Charles [3 ]
Wells, Alan [2 ]
Haidar, Ghady [4 ]
机构
[1] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA
[3] Univ Pittsburgh, Med Ctr, Clin Labs, Pittsburgh, PA USA
[4] Univ Pittsburgh, Div Infect Dis, Sch Med, Pittsburgh, PA USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2021年 / 8卷 / 07期
基金
美国国家卫生研究院;
关键词
antibody; COVID; 19; vaccine; hematological malignancy; SARS; CoV; 2; COVID-19;
D O I
10.1093/ofid/ofab353
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We measured severe acute respiratory syndrome coronavirus 2 immunoglobulin G responses in 67 patients with hematological malignancies after 2 messenger RNA vaccine doses. Forty-six percent were nonresponders; patients with B-cell chronic lymphocytic leukemia were at highest risk (77% nonresponders). Patients with hematological malignancies should continue wearing masks and socially distancing. Studies of revaccination, boosters, and humoral immune correlates of protection are needed.
引用
收藏
页数:5
相关论文
共 35 条
  • [1] American Society for Transplantation and Cellular Therapy, 2021, ASH ASTCT COVID 19 V
  • [2] [Anonymous], CBS NEWS
  • [3] Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer
    Avanzato, Victoria A.
    Matson, M. Jeremiah
    Seifert, Stephanie N.
    Pryce, Rhys
    Williamson, Brandi N.
    Anzick, Sarah L.
    Barbian, Kent
    Judson, Seth D.
    Fischer, Elizabeth R.
    Martens, Craig
    Bowden, Thomas A.
    de Wit, Emmie
    Riedo, Francis X.
    Munster, Vincent J.
    [J]. CELL, 2020, 183 (07) : 1901 - +
  • [4] Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
    Aydillo, Teresa
    Babady, N. Esther
    Kamboj, Mini
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26) : 2586 - 2588
  • [5] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
  • [6] Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
    Boyarsky, Brian J.
    Werbel, William A.
    Avery, Robin K.
    Tobian, Aaron A. R.
    Massie, Allan B.
    Segev, Dorry L.
    Garonzik-Wang, Jacqueline M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (21): : 2204 - 2206
  • [7] Centers for Disease Control and Prevention, 2021, YOU VE BEEN FULL VAC
  • [8] Early experience with SARs-CoV-2 mRNA vaccine breakthrough among kidney transplant recipients
    Chenxi Song, Chelsey
    Christensen, Johanna
    Kumar, Dhiren
    Vissichelli, Nicole
    Morales, Megan
    Gupta, Gaurav
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [9] The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
    Chodick, Gabriel
    Tene, Lilac
    Rotem, Ran S.
    Patalon, Tal
    Gazit, Sivan
    Ben-Tov, Amir
    Weil, Clara
    Goldshtein, Inbal
    Twig, Gilad
    Cohen, Dani
    Muhsen, Khitam
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 74 (03) : 472 - 478
  • [10] Cohen MS, 2021, JAMA-J AM MED ASSOC, V326, P46, DOI [10.1001/jama.2021.88282021., 10.1001/jama.2021.8828]